Home Careers Contact

Price: 3.85

Change: 0.00

Day High: 3.85
Day Low: 3.75
Volume: 923,861

4:00 PM ET | May 26, 2017
Delayed 20 min., by eSignal.



Shareholder Tools

Press Releases

Company News
View Summary Cempra Reports Third Quarter 2016 Financial Results and Provides Corporate Update
Oct 27, 2016
PDF 32.9 KB Add to Briefcase
View Summary Cempra to Report Third Quarter 2016 Financial Results
Oct 25, 2016
PDF 14.9 KB Add to Briefcase
View Summary Cempra Presents Analysis Showing Rates of Failure for Existing CABP Antibiotics From Claims Database at Academy of Managed Care Pharmacy Meeting
Oct 4, 2016
PDF 22.2 KB Add to Briefcase
View Summary Cempra Announces Anti-NASH Effects of Solithromycin: Interim Results From Phase 2 Study
Sep 29, 2016
PDF 72.1 KB Add to Briefcase
View Summary Cempra to Present at Three Upcoming Investor Conferences
Sep 1, 2016
PDF 14.0 KB Add to Briefcase
View Summary Cempra to Present Solithromycin at FDA Antimicrobial Drugs Advisory Committee Meeting on November 4, 2016
Aug 30, 2016
PDF 15.7 KB Add to Briefcase
View Summary Cempra's Pivotal Phase 3 SOLITAIRE-IV Study of IV to Oral Solithromycin Published in Clinical Infectious Diseases
Aug 25, 2016
PDF 17.0 KB Add to Briefcase
View Summary Cempra Announces European Medicines Agency Validates MAA for Solithromycin for Treatment of CABP
Aug 23, 2016
PDF 15.9 KB Add to Briefcase
View Summary Cempra Appoints Dr. David Zaccardelli to Board of Directors
Aug 11, 2016
PDF 15.8 KB Add to Briefcase
View Summary Cempra Reports Second Quarter 2016 Financial Results and Provides Corporate Update
Aug 1, 2016
PDF 27.8 KB Add to Briefcase
Showing 21-30 of 232 Page: 1 2 3 4 5 6 7 ... 24  Previous 10 | Next 10
Add to Briefcase = add release to Briefcase